Cartilage Diseases Epidemiology Forecast 2025-2034

Recent studies indicate that cartilage diseases range from highly prevalent conditions such as osteoarthritis, which is reported to occur in around 37% of the adult population in the United States, to rare conditions of genetic origin such as spondyloepimetaphyseal dysplasia, aggrecan type, which is estimated affect fewer than 1000 individuals in the United States.

Cartilage Diseases Epidemiology Forecast Report Coverage

The “Cartilage Diseases Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of Cartilage Diseases. It projects the future incidence and prevalence rates of cartilage diseases across various populations. The study covers age, gender, and type as major determinants of the cartilage disease-affected population. The report highlights patterns in the prevalence of cartilage diseases over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of cartilage diseases in the 8 major markets.

Regions Covered

• The United States
• EU-4 (Germany, France, Italy, Spain) and the United Kingdom
• Japan
• India

Cartilage Diseases: Disease Overview

A cartilage disease refers to a condition that affects the cartilage, the flexible tissue found in joints, the rib cage, the ear, the nose, and other parts of the body. Common symptoms of cartilage diseases include pain, stiffness, swelling, and inflammation in the affected joint or area. In some cases, cartilage issues can potentially impact mobility and quality of life. Chronic cartilage diseases are also reported to cause visible deformities due to cartilage damage as well as reduced range of motion among patients. Osteoarthritis is a common cartilage disease, often caused by aging, wear and tear, joint injuries, and genetic predispositions.

Cartilage Diseases: Treatment Overview

The type of cartilage disease, severity of the symptoms, and the patient's profile influence the treatment approach. Lifestyle modifications such as reducing body weight and engaging in low-impact exercises are commonly recommended to manage pain and improve joint function. Further, nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids are often prescribed for addressing inflammation and pain, especially for conditions like osteoarthritis. Hyaluronic acid injections and platelet-rich plasma (PRP) therapy are some other popular treatment options available for patients suffering from cartilage diseases.

Epidemiology

The cartilage diseases epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for cartilage diseases by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for cartilage diseases and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• As per a 2018 study published in the Journal of the International Society for Matrix Biology, cartilage diseases such as osteoarthritis which is reported to occur in around 37% of the adult population in the United States, are highly prevalent globally. On the other hand, cartilage diseases of genetic origin such as spondyloepimetaphyseal dysplasia, aggrecan type, are rare and estimated to affect fewer than 1000 individuals in the United States.
• An estimated 528 million individuals were living with osteoarthritis globally in 2019, an increase of 113% since 1990, according to a systematic analysis for the Global Burden of Disease Study 2019.
• Studies indicate that approximately 73% of people affected by osteoarthritis are over 55 years old. Further, 60% of the patient pool is women which is probably due to differences in cartilage characteristics along with the risk of degeneration through sex-dependent gene expression.
• The Centers for Disease Control and Prevention (CDC) recognizes osteoarthritis as one of the leading causes of disability in adults, affecting over 32.5 million adults in the United States.

Country-wise Cartilage Diseases Epidemiology

The cartilage diseases epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of cartilage diseases differs between countries due to factors such as age distribution, differences in lifestyle patterns, genetic predispositions, injury rates, and access to healthcare services, among others. In the United Kingdom, around 10% of adults are affected by clinical symptoms of osteoarthritis. It is also reported that the number of cases of osteoarthritis patients has increased by 16% in the country over the past two decades, attributed primarily to an increase in life expectancy.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of cartilage diseases based on several factors.
• Cartilage Diseases Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India)
• The report helps to identify the patient population and the unmet needs of cartilage diseases are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of cartilage disease epidemiology in the 8 major markets?
• What will be the total number of patients with cartilage diseases across the 8 major markets during the forecast period?
• What was the country-wise prevalence of cartilage diseases in the 8 major markets in the historical period?
• Which country will have the highest number of cartilage disease patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of cartilage diseases during the forecast period of 2025-2034?
• What are the currently available treatments for cartilage diseases?
• What are the disease risks, signs, symptoms, and unmet needs of cartilage diseases?

This product will be delivered within 3-5 business days.